The National Health Service is seeking feedback on its plans to expand its pioneering subscription-style drug contracts to develop lifesaving antibiotics and tackle the problem of antimicrobial resistance.
The National Health Service in England could double the annual payments it offers companies under its pioneering subscription-style contracts for incentivizing them to develop new antibiotics from £10m ($12.90m) to £20m, where outstanding clinically based criteria are met.
In proposals announced today for a 12-week public consultation, NHS England is also seeking input on which products to prioritize,...
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.
The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.
